tiprankstipranks
Trending News
More News >
CYBERDYNE Inc. (JP:7779)
:7779
Advertisement

CYBERDYNE (7779) AI Stock Analysis

Compare
2 Followers

Top Page

JP:7779

CYBERDYNE

(7779)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
¥178.00
▲(3.49% Upside)
CYBERDYNE's overall stock score is primarily impacted by its financial performance and valuation challenges. The company's declining revenues, negative profit margins, and poor cash flow generation are significant concerns. Additionally, the negative P/E ratio and lack of dividend yield further detract from its attractiveness. Technical analysis suggests bearish momentum, adding to the cautious outlook.
Positive Factors
Balance Sheet Health
CYBERDYNE's low leverage indicates strong balance sheet health, providing financial stability and flexibility for future investments and growth opportunities.
Strategic Partnerships
Strategic partnerships enhance market reach and technology adoption, supporting long-term revenue growth and innovation in CYBERDYNE's core sectors.
Product Innovation
Innovative products like the HAL exoskeleton position CYBERDYNE as a leader in assistive technology, driving demand and potential market expansion.
Negative Factors
Declining Revenue
Declining revenues indicate challenges in maintaining market share and demand, which could impact long-term financial performance and growth prospects.
Profitability Issues
Negative profit margins reflect operational inefficiencies and financial strain, potentially hindering reinvestment and growth capabilities over time.
Cash Flow Challenges
Negative cash flows limit the company's ability to fund operations and invest in growth, posing a risk to financial sustainability and strategic initiatives.

CYBERDYNE (7779) vs. iShares MSCI Japan ETF (EWJ)

CYBERDYNE Business Overview & Revenue Model

Company DescriptionCYBERDYNE (7779) is a Japanese robotics and technology company specializing in the development of advanced robotic systems designed to assist and enhance human capabilities. The company operates primarily in the healthcare and industrial sectors, focusing on products such as the HAL (Hybrid Assistive Limb) exoskeleton, which is used for rehabilitation and assistance for individuals with mobility impairments. CYBERDYNE also engages in research and development of robotics technologies for various applications, including disaster response and industrial automation.
How the Company Makes MoneyCYBERDYNE generates revenue through multiple channels, including the sale of its robotic products such as the HAL exoskeleton, which is marketed to hospitals and rehabilitation centers. The company also earns income from leasing its robotic systems and providing maintenance and support services. Additionally, CYBERDYNE has formed strategic partnerships with healthcare providers and research institutions, which help to expand its market reach and promote the adoption of its technologies. Grants and funding for research projects further contribute to its revenue streams, particularly in the development of new applications and enhancements of existing products.

CYBERDYNE Financial Statement Overview

Summary
CYBERDYNE faces financial challenges with declining revenues and profitability issues, as reflected in negative margins and cash flows. The balance sheet remains a strength with low leverage, but the company needs to address operational inefficiencies and improve cash flow generation to enhance financial health.
Income Statement
45
Neutral
CYBERDYNE's income statement shows a declining revenue trend with a negative revenue growth rate of -3.54% in the TTM. The company has a gross profit margin of 54.13%, which is relatively strong, but the net profit margin is negative at -13.14%, indicating losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges.
Balance Sheet
60
Neutral
The balance sheet is relatively stable with a low debt-to-equity ratio of 0.011, suggesting low leverage. However, the return on equity is negative at -1.43%, indicating inefficiencies in generating returns from equity. The equity ratio is strong, showing a solid capital structure.
Cash Flow
40
Negative
CYBERDYNE's cash flow statement reveals negative operating and free cash flows, with a significant decline in free cash flow growth at -59.64% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is positive, suggesting some ability to cover net losses.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.23B4.38B4.35B3.29B2.15B1.88B
Gross Profit2.26B2.37B2.39B1.79B1.28B1.30B
EBITDA268.00M16.00M-2.00M873.00M116.00M892.00M
Net Income-337.00M-577.00M-1.48B-298.00M-498.00M-59.00M
Balance Sheet
Total Assets48.95B48.55B50.00B50.19B48.12B47.81B
Cash, Cash Equivalents and Short-Term Investments5.14B14.86B16.66B17.31B5.68B6.70B
Total Debt402.00M434.00M632.00M669.00M575.00M421.00M
Total Liabilities9.16B8.95B9.52B8.20B4.33B3.55B
Stockholders Equity39.76B39.58B40.75B42.10B43.41B43.78B
Cash Flow
Free Cash Flow-293.00M-735.00M-1.07B-652.00M-1.85B-620.00M
Operating Cash Flow-60.00M-430.00M-850.00M-143.00M-775.00M-215.00M
Investing Cash Flow460.00M2.33B-2.08B2.17B-2.79B-244.00M
Financing Cash Flow-216.00M-216.00M160.00M14.00M617.00M1.30B

CYBERDYNE Technical Analysis

Technical Analysis Sentiment
Negative
Last Price172.00
Price Trends
50DMA
182.38
Negative
100DMA
186.21
Negative
200DMA
181.41
Negative
Market Momentum
MACD
-4.09
Positive
RSI
44.09
Neutral
STOCH
33.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7779, the sentiment is Negative. The current price of 172 is below the 20-day moving average (MA) of 175.40, below the 50-day MA of 182.38, and below the 200-day MA of 181.41, indicating a bearish trend. The MACD of -4.09 indicates Positive momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 33.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7779.

CYBERDYNE Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥16.44B13.563.65%-4.36%-14.92%
69
Neutral
¥31.34B10.062.78%6.72%20.01%
66
Neutral
¥81.83B21.202.38%4.36%79.43%
58
Neutral
¥12.61B3.13%3.59%-163.08%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$38.71B-35.38-49.32%45.67%29.44%
45
Neutral
$39.15B-114.02-0.46%-4.30%82.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7779
CYBERDYNE
172.00
-12.00
-6.52%
JP:7777
3-D Matrix
335.00
223.00
199.11%
JP:4549
Eiken Chemical Co., Ltd.
2,457.00
347.84
16.49%
JP:6678
Techno Medica Co., Ltd.
2,054.00
315.14
18.12%
JP:6823
Rion Co., Ltd.
2,578.00
156.74
6.47%
JP:7600
Japan Medical Dynamic Marketing, Inc.
476.00
-139.37
-22.65%

CYBERDYNE Corporate Events

CYBERDYNE Selected for Ukraine Reconstruction Subsidy
Oct 7, 2025

CYBERDYNE has been selected for a subsidy under the Japanese government’s program to support Ukraine’s reconstruction. The company will establish a next-generation Cybernics treatment center in Ukraine, partnering with UNBROKEN in Lviv, to aid in the social reintegration of war-affected individuals and restore medical infrastructure.

The most recent analyst rating on (JP:7779) stock is a Hold with a Yen183.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.

CYBERDYNE Reports Revenue Decline but Improved Profits in Q1 2025
Aug 14, 2025

CYBERDYNE, INC. reported a decrease in revenue for the three months ending June 30, 2025, with a 13.4% drop compared to the previous year. Despite the revenue decline, the company saw a notable improvement in profits attributable to owners, indicating potential operational efficiencies or cost management strategies. The company did not provide a forecast for the fiscal year ending March 31, 2026, due to uncertainties in its market.

The most recent analyst rating on (JP:7779) stock is a Buy with a Yen365.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 25, 2025